Recent from talks
Ipratropium bromide
Knowledge base stats:
Talk channels stats:
Members stats:
Ipratropium bromide
Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic medication which is applied by different routes: inhaler, nebulizer, or nasal spray, for different reasons.
The inhalant opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease (COPD) and asthma. It is used by inhaler or nebulizer. Onset of action is typically within 15 to 30 minutes and lasts for three to five hours.
The nasal spray prevents the glands in the nose from producing large amounts of fluid. It is used to treat rhinorrhea (runny nose) caused by allergic rhinitis, nonallergic rhinitis, and the common cold. It is used by metered-dose manual pump spray. Onset of action is within an hour.
Common side effects of inhalant use include dry mouth, cough, inflammation of the airways, and shortness of breath. Potentially serious side effects include urinary retention, worsening spasms of the airways, and a severe allergic reaction. It appears to be safe in pregnancy and breastfeeding. Ipratropium is a short-acting muscarinic antagonist, which works by causing smooth muscles to relax.
Common side effects of nasal spray may include headache, dry nose, dry mouth or throat, nasal or throat irritation, nosebleeds, bad taste in mouth, nausea, dizziness, or constipation. Potentially serious side effects are unusual, but include severe allergic reaction, eye pain or change in vision, or urinary retention. It is considered safe during pregnancy. Ipratropium nasal is not expected to harm an unborn baby .
Ipratropium bromide was patented in 1966, and approved for medical use in 1974. It is on the World Health Organization's List of Essential Medicines, the most important medicines needed in a health system. Ipratropium is available as a generic medication. In 2023, it was the 268th most commonly prescribed medication in the United States, with more than 900,000 prescriptions.
Ipratropium as an inhalant can be used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma exacerbation. It is supplied in a canister for use in an inhaler or in single dose vials for use in a nebulizer.
It is also used to treat and prevent minor and moderate bronchial asthma, especially asthma that is accompanied by cardiovascular system diseases, as it has been shown to produce fewer cardiovascular side effects.
Hub AI
Ipratropium bromide AI simulator
(@Ipratropium bromide_simulator)
Ipratropium bromide
Ipratropium bromide, sold under the trade name Atrovent among others, is a type of anticholinergic medication which is applied by different routes: inhaler, nebulizer, or nasal spray, for different reasons.
The inhalant opens up the medium and large airways in the lungs. It is used to treat the symptoms of chronic obstructive pulmonary disease (COPD) and asthma. It is used by inhaler or nebulizer. Onset of action is typically within 15 to 30 minutes and lasts for three to five hours.
The nasal spray prevents the glands in the nose from producing large amounts of fluid. It is used to treat rhinorrhea (runny nose) caused by allergic rhinitis, nonallergic rhinitis, and the common cold. It is used by metered-dose manual pump spray. Onset of action is within an hour.
Common side effects of inhalant use include dry mouth, cough, inflammation of the airways, and shortness of breath. Potentially serious side effects include urinary retention, worsening spasms of the airways, and a severe allergic reaction. It appears to be safe in pregnancy and breastfeeding. Ipratropium is a short-acting muscarinic antagonist, which works by causing smooth muscles to relax.
Common side effects of nasal spray may include headache, dry nose, dry mouth or throat, nasal or throat irritation, nosebleeds, bad taste in mouth, nausea, dizziness, or constipation. Potentially serious side effects are unusual, but include severe allergic reaction, eye pain or change in vision, or urinary retention. It is considered safe during pregnancy. Ipratropium nasal is not expected to harm an unborn baby .
Ipratropium bromide was patented in 1966, and approved for medical use in 1974. It is on the World Health Organization's List of Essential Medicines, the most important medicines needed in a health system. Ipratropium is available as a generic medication. In 2023, it was the 268th most commonly prescribed medication in the United States, with more than 900,000 prescriptions.
Ipratropium as an inhalant can be used for the treatment of chronic obstructive pulmonary disease (COPD) and asthma exacerbation. It is supplied in a canister for use in an inhaler or in single dose vials for use in a nebulizer.
It is also used to treat and prevent minor and moderate bronchial asthma, especially asthma that is accompanied by cardiovascular system diseases, as it has been shown to produce fewer cardiovascular side effects.
Recent media